Healthcare and Pharma Marketing: What’s Changing

Digital marketing in healthcare and pharma is changing faster than most organisations can adapt to it. Patients are searching, comparing, and making decisions online before they ever speak to a clinician or sales rep. Meanwhile, the regulatory environment has tightened, third-party data is eroding, and the channels that worked five years ago are under pressure from every direction.

The organisations pulling ahead are not the ones chasing every new platform. They are the ones who have built a clear commercial model, made smart channel choices, and invested in first-party data before they needed it. The ones falling behind are still running the same playbook they used in 2019 and wondering why it is getting more expensive and less effective.

If you want a broader frame for how these channel decisions fit into commercial strategy, the Go-To-Market and Growth Strategy hub covers the structural thinking behind market entry, channel mix, and growth planning across sectors including healthcare.

Why Healthcare and Pharma Are Structurally Different From Other Verticals

I have run campaigns across more than 30 industries. Healthcare and pharma sit in a category of their own, not because they are more complex in a technical sense, but because the consequences of getting things wrong are different in kind, not just in degree. A bad campaign in retail costs you margin. A bad campaign in pharma can cost you your licence to operate.

That changes how you build the marketing function. Compliance is not a filter you apply at the end of the process. It has to be baked into briefing, channel selection, creative development, and measurement. Organisations that treat it as a sign-off step rather than a structural input spend enormous amounts of time reworking campaigns that should never have been built the way they were in the first place.

There is also a dual audience problem that most other sectors do not face at the same scale. You are often marketing to patients and healthcare professionals simultaneously, with completely different messages, different channels, different regulatory requirements, and different buying psychology. The patient wants to understand their condition and their options. The HCP wants clinical evidence, dosing information, and peer validation. Conflating these audiences, or trying to serve both with the same content, is one of the most common and expensive mistakes I see.

Forrester has written usefully about the go-to-market struggles specific to healthcare devices and diagnostics, and many of the structural observations apply more broadly across pharma and health services. The core tension is the same: the buying process is long, multi-stakeholder, and heavily influenced by factors that are hard to attribute to any single marketing touchpoint.

The First-Party Data Imperative

When I was at iProspect, we managed significant media budgets across clients in regulated sectors. The ones who had invested in their own data infrastructure, CRM, email lists, owned content, were consistently in a stronger position when platform rules changed or costs shifted. The ones who had built their entire model on rented audiences found themselves exposed every time Google, Meta, or a data broker changed the terms.

In healthcare and pharma, that vulnerability is now acute. Third-party cookie deprecation, Apple’s privacy changes, and increasing regulatory scrutiny of health data have fundamentally altered what you can do with bought or borrowed data. The organisations that saw this coming and started building first-party data assets three or four years ago are in a materially different position today.

First-party data in this context means email lists built on genuine consent, patient and HCP portals with meaningful engagement, CRM systems that capture interaction history across touchpoints, and content platforms that generate direct subscriptions. It means knowing who your audience is because they chose to tell you, not because a data broker inferred it.

Building this is not glamorous work. It requires investment in content quality, user experience, and data architecture that does not show up in short-term campaign metrics. But it is the only durable foundation for digital marketing in a sector where the rules around third-party data are going to keep tightening.

If your organisation has not yet done a systematic audit of its digital infrastructure from a data and conversion perspective, the website analysis checklist for sales and marketing strategy is a useful starting point. The questions it raises about data capture, user experience, and commercial alignment apply directly to healthcare and pharma digital properties.

Endemic Advertising: The Smarter Way to Reach HCPs

Broad programmatic advertising has always been a blunt instrument for reaching healthcare professionals. You pay for reach across a network, hope the targeting holds, and accept that a significant portion of your impressions are going to people who will never write a prescription or make a procurement decision. The waste is structural, not a function of poor execution.

Endemic advertising changes that equation. By placing ads within the specific publications, platforms, and content environments that HCPs actually use, you get contextual relevance alongside audience quality. A cardiologist reading a clinical cardiology journal online is in a completely different mindset than the same person scrolling a general news feed. The context shapes receptivity in ways that targeting parameters alone cannot replicate.

The endemic advertising overview here covers the mechanics in more detail, but the strategic point is straightforward. In healthcare and pharma, where your audience is small, professional, and expensive to reach, endemic placements often deliver better qualified attention per pound spent than broad programmatic, even when the CPMs look higher on paper. Cost per relevant impression is a more useful metric than cost per thousand impressions when your total addressable audience is measured in thousands rather than millions.

This is particularly true for specialty pharma and medical device marketing, where the prescribing or purchasing audience might be a few thousand specialists globally. Paying a premium to reach them in context is almost always the right trade-off.

Paid Search in a Regulated Environment

Early in my career, I ran a paid search campaign at lastminute.com for a music festival. Within roughly a day, a relatively simple campaign had generated six figures of revenue. The feedback loop was almost instantaneous. You could see what was working, adjust, and scale within hours. It was the kind of campaign that makes paid search feel like the most logical thing in the world.

Healthcare and pharma paid search is the opposite of that experience in almost every dimension. The approval cycles are long. The ad copy restrictions are significant. Condition-specific terms often trigger policy reviews. And the cost per click in competitive therapeutic areas can be genuinely eye-watering. None of that makes the channel unworkable. It makes it harder to run badly, which is actually a useful filter.

The organisations that succeed in pharma paid search have invested in three things. First, a compliance workflow that is fast enough to be commercially viable, not a bureaucratic process that adds three weeks to every campaign iteration. Second, a clear understanding of what they can and cannot say in ad copy, so creative teams are not writing headlines that will never be approved. Third, a landing page strategy that converts the traffic they do generate, because at those CPCs, waste is expensive.

For patient-facing campaigns, the intent signals in search are often the highest quality leads you will generate anywhere in the channel mix. Someone searching for a specific condition, treatment, or medication is further along in their decision process than almost any other audience you can reach. The compliance overhead is real, but the intent quality justifies it.

Content as a Commercial Asset, Not a Marketing Activity

When I started in marketing around 2000, I asked for budget to build a website and was told no. Rather than accept that, I taught myself to code and built it anyway. The lesson I took from that was not about resourcefulness, though that helped. It was about the relationship between content and commercial outcomes. Even then, a website was not a marketing activity. It was a business asset that either worked or did not.

Healthcare and pharma organisations still struggle with this distinction. Content gets treated as a marketing deliverable rather than a commercial asset. The question asked is “how much content are we producing?” rather than “what is this content doing for us commercially?” The result is a lot of content that exists, very little that performs.

The organisations getting this right are building content around specific patient or HCP decision points. They are mapping the questions their audience is asking at each stage of the consideration process and creating content that genuinely answers those questions, not content that promotes their product while pretending to be educational. The distinction matters because audiences can tell the difference, and so can search algorithms.

For HCP-facing content, peer-reviewed evidence, clinical data, and genuine educational value are the currency. For patient-facing content, clarity, empathy, and practical utility matter more than production values. Neither audience is served by content that is primarily about the brand.

The Vidyard analysis of why go-to-market feels harder makes a point that resonates here: the problem is rarely channel access. It is that organisations have not done the work to understand what their audience actually needs at each stage of the decision process. Healthcare and pharma are not exceptions to that.

The HCP Digital Experience Has Changed Permanently

The shift in how healthcare professionals engage with pharma companies digitally accelerated sharply during the pandemic years and has not reversed. Reps who once had regular face-to-face access to prescribers now find that access restricted or mediated through digital channels. The digital touchpoint has moved from supplementary to primary for a significant proportion of HCP interactions.

This has two implications that are worth separating. First, the quality of your digital HCP experience now directly affects commercial outcomes in ways it did not five years ago. A clunky portal, a PDF-heavy resource library that is hard to handle, or a medical information request process that takes days to respond to, these are not just UX problems. They are commercial problems. The HCP who cannot find what they need from you will find it elsewhere, and that shapes prescribing behaviour.

Second, the data generated by HCP digital interactions is genuinely valuable if you have the infrastructure to use it. Which content is being accessed, at what stage of the product lifecycle, by which specialties, this tells you something real about where your clinical story is landing and where it is not. Most organisations are not capturing or acting on this data systematically.

The digital marketing due diligence framework is relevant here for organisations assessing whether their current digital infrastructure is fit for purpose, either for their own operations or as part of a commercial evaluation of a target business. The questions it raises about channel performance, data quality, and attribution are directly applicable to the HCP digital experience.

Demand Generation Versus Demand Capture

One of the most persistent strategic errors I see in healthcare and pharma marketing is treating demand capture as demand generation. Paid search captures existing intent. It does not create it. If a patient does not know a condition exists, or does not know a treatment is available, they are not going to search for it. No amount of paid search budget fixes that problem.

Genuine demand generation in this sector requires channels that reach audiences before they are searching. That means condition awareness campaigns, patient education content, HCP outreach that builds understanding of unmet need, and in some cases, disease state education that precedes any product-specific messaging. This is longer-cycle work. It does not show up in 30-day attribution windows. And it is exactly the kind of investment that gets cut first when budgets are under pressure.

The organisations that understand the difference between demand generation and demand capture build their channel mix accordingly. They do not expect paid search to do the work of awareness. They invest in channels that build the category before they invest in channels that harvest it. The market penetration frameworks that apply in other sectors apply here too, the sequencing of awareness, consideration, and conversion is not optional, it is structural.

This is also where the comparison with B2B financial services marketing is instructive. Both sectors deal with long decision cycles, high regulatory scrutiny, and audiences that require education before they are ready to act. The channel logic that works in financial services, investing in thought leadership and education before pushing for conversion, applies directly to pharma and healthcare B2B.

Measurement in a Sector Where Attribution Is Genuinely Hard

I have sat on Effie Award juries and seen how the industry talks about marketing effectiveness when it is being honest with itself. The gap between what gets measured and what actually drives outcomes is wide in most sectors. In healthcare and pharma, that gap is wider still.

The patient experience from first digital touchpoint to prescription or treatment is long, non-linear, and involves human intermediaries, clinicians, pharmacists, insurers, whose decisions are not captured in any marketing attribution model. The HCP experience from awareness to prescribing behaviour is even harder to track. You can measure digital engagement. You cannot easily connect it to what happens in the consulting room.

The answer is not to stop measuring. It is to be honest about what your measurements are actually telling you. Digital engagement metrics tell you about digital engagement. They are a proxy for commercial outcomes, not a direct measure of them. Organisations that treat click-through rates and page views as evidence of marketing effectiveness are fooling themselves. Organisations that triangulate digital metrics with commercial outcomes, prescription data, market share, HCP engagement scores, are building a more honest picture.

For organisations with field sales teams working alongside digital channels, the pay per appointment model offers one way to create a cleaner link between digital marketing activity and commercial outcomes. It does not solve the attribution problem entirely, but it creates a more direct line between marketing spend and sales activity than most digital metrics provide.

Organisational Structure and the Marketing Framework Problem

One of the less discussed but genuinely important trends in pharma marketing is the structural tension between global brand teams and local market execution. A global brand team sets the strategy, the messaging, the creative platform, the compliance guardrails. The local market has to execute within those parameters in a regulatory and cultural context that the global team often does not fully understand.

The result is frequently a compromise that serves neither the global brand nor the local market particularly well. The global team feels like their strategy is being diluted. The local team feels like they are being forced to run campaigns that do not fit their market. And the patient or HCP at the end of the chain gets a digital experience that feels neither locally relevant nor globally coherent.

The corporate and business unit marketing framework for B2B companies addresses this structural tension directly. The principles around where decisions should sit, what should be centralised versus localised, and how to build a framework that enables local execution without losing brand coherence, are directly applicable to pharma organisations handling the global-local tension.

Getting this structure right is not an organisational theory exercise. It has direct commercial implications. Markets that are forced to run campaigns that do not fit their context underperform. Markets that are given too much autonomy fragment the brand and create compliance exposure. The organisations that have solved this problem have usually done it by being very clear about what is non-negotiable globally and genuinely flexible about everything else.

BCG’s work on commercial transformation in go-to-market strategy is worth reading in this context. The structural questions it raises about how marketing organisations are built and how they connect to commercial outcomes are as relevant to pharma as to any other sector.

More thinking on how to build marketing strategy that connects to commercial outcomes, rather than just marketing activity, is available across the Go-To-Market and Growth Strategy hub, covering everything from channel selection to market entry frameworks.

What the Next Few Years Actually Look Like

The trends that will shape healthcare and pharma marketing over the next three to five years are not mysterious. They are visible now. AI-assisted content production is already changing the economics of content at scale, though the compliance review requirement means the speed gains are more modest than in other sectors. Personalisation at the HCP level is becoming more feasible as data infrastructure improves, though the privacy constraints mean the personalisation has to be earned through consent rather than inferred from behaviour. And the shift toward value-based healthcare is changing the conversation that pharma needs to have with payers and providers, which in turn changes the marketing messages that matter.

None of these trends require a wholesale reinvention of how healthcare and pharma organisations market themselves. They require the same thing they have always required: a clear understanding of the audience, a channel mix that matches the buying process, content that genuinely serves the people it is aimed at, and measurement that is honest about what it can and cannot tell you.

The organisations that will do well are the ones that resist the temptation to chase every new platform or technology and instead invest in the fundamentals that compound over time: first-party data, content quality, commercial alignment, and a marketing structure that enables rather than constrains local execution. That is not a particularly exciting prescription. But in my experience, the unexciting prescriptions are usually the ones that work.

About the Author

Keith Lacy is a marketing strategist and former agency CEO with 20+ years of experience across agency leadership, performance marketing, and commercial strategy. He writes The Marketing Juice to cut through the noise and share what works.

Frequently Asked Questions